Compare ADMA Biologics Inc (ADMA) vs Fox Corp Class B (FOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Fox Corp Class B — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Fox Corp Class B trades at $48.37 (market cap $21.80B). The key difference: Fox Corp Class B is far larger — about 10.2× ADMA Biologics Inc's market cap, and Fox Corp Class B pays a 1.14% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | FOX | |
|---|---|---|
Market Cap | $2.13B | $21.80B |
Sector | Health | Media |
52-Week High | $20.38 | $67.76 |
52-Week Low | $7.60 | $44.39 |
Enterprise Value | $2.20B | $25.77B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
FOX stock trades at $49.20, down 2.69% on the day, amid bearish technical signals and recent volatility following its $22 billion Roku acquisition announcement. The company shows strong fundamental performance with three consecutive quarterly earnings beats, revenue growth to $16.3 billion in 2025, and improved cash flow generation. However, technical indicators signal bearish momentum with the stock trading near support levels while analyst sentiment remains mixed with 43% buy ratings.
The outlook balances strong operational execution against acquisition integration risks. FOX's attractive valuation (P/E 13.14) and streaming expansion through Roku present growth opportunities, but high leverage and competitive pressures create near-term uncertainty. Investor focus remains on Q2 2026 earnings delivery and Roku synergy realization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
